0000914190-19-000460.txt : 20191206 0000914190-19-000460.hdr.sgml : 20191206 20191206165056 ACCESSION NUMBER: 0000914190-19-000460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191204 FILED AS OF DATE: 20191206 DATE AS OF CHANGE: 20191206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WIENS HAROLD J CENTRAL INDEX KEY: 0001197788 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 191273622 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-12-04 0000842023 BIO-TECHNE Corp TECH 0001197788 WIENS HAROLD J 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 1 0 0 0 Common Stock 2019-12-04 4 M 0 2000 87.83 A 7221 D Common Stock 2019-12-04 4 S 0 485 216.4747 D 6736 D Common Stock 2019-12-04 4 S 0 514 217.2852 D 6222 D Common Stock 2019-12-04 4 S 0 921 218.7545 D 5301 D Common Stock 2019-12-04 4 S 0 80 219.3139 D 5221 D Stock Option (right to buy) 87.83 2019-12-04 4 M 0 2000 0 D 2014-05-15 2024-05-15 Common Stock 2000 0 D Stock Option (right to buy) 91.78 2014-10-30 2024-10-30 Common Stock 4000 4000 D Stock Option (right to buy) 87.34 2016-10-29 2025-10-28 Common Stock 4260 4260 D Stock Option (right to buy) 101.19 2017-10-26 2026-10-26 Common Stock 3985 3985 D Stock Option (right to buy) 125.05 2018-10-25 2027-10-26 Common Stock 3125 3125 D Stock Option (right to buy) 179.84 2019-10-24 2028-10-25 Common Stock 1898 1898 D Stock Option (right to buy) 201.64 2029-10-24 Common Stock 2011 2011 D The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Brenda S. Furlow as Attorney-in-Fact for Harold J. Wiens pursuant to Power of Attorney previously filed. 2019-12-06